Otsuka Holdings Co., Ltd. (TYO:4578)
Japan
· Delayed Price · Currency is JPY 10,145
+275 (2.79%)
Mar 10, 2026, 1:15 PM JST
Otsuka Holdings Revenue
In the year 2025, Otsuka Holdings had annual revenue of 2.47T JPY with 5.97% growth. Otsuka Holdings had revenue of 650.15B in the quarter ending December 31, 2025, with 8.40% growth.
Revenue
2,468.89B
Revenue Growth
+5.97%
P/S Ratio
2.11
Revenue / Employee
65.39M
Employees
37,758
Market Cap
5,209.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2,468.89B | 139.03B | 5.97% |
| Dec 31, 2024 | 2,329.86B | 311.29B | 15.42% |
| Dec 31, 2023 | 2,018.57B | 280.57B | 16.14% |
| Dec 31, 2022 | 1,738.00B | 239.72B | 16.00% |
| Dec 31, 2021 | 1,498.28B | 75.45B | 5.30% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Daiichi Sankyo Company | 2,052.15B |
| Astellas Pharma | 2,060.61B |
| Chugai Pharmaceutical | 1,257.94B |
| Ono Pharmaceutical | 509.35B |
| Kyowa Kirin | 496.83B |
| Santen Pharmaceutical | 287.99B |
| JCR Pharmaceuticals | 37.55B |
| Perseus Proteomics | 140.41M |
Otsuka Holdings News
- 20 days ago - Full Year 2025 Otsuka Holdings Co Ltd Earnings Presentation Transcript - GuruFocus
- 24 days ago - Otsuka Holdings FY25 Profit Rises, Sees Weak Profit In H1, FY26 - Nasdaq
- 3 months ago - US FDA approves Otsuka's kidney disease drug - Reuters
- 5 months ago - Shares of Asian drugmakers drop after Trump threatens tariffs - Reuters